Drug intelligence / Profile preview

68Ga-NYM005

Development stage: Phase 2
Lead developer: Norroy Bioscience
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

68Ga-NYM005 is a small-molecule radiopharmaceutical designed as a diagnostic PET/CT imaging agent. It targets carbonic anhydrase IX (CAIX), a protein highly expressed in clear cell renal cell carcinoma. By binding to CAIX, the radiolabeled compound enables visualization of primary and metastatic lesions in patients with this cancer type. The drug is currently being evaluated for its pharmacokinetics, biodistribution, radiation dose, and safety profile in clinical trials for renal cell carcinoma and metastatic clear cell renal cell carcinoma[2][4][5]. The developer is Norroy Bioscience.

Other names: 68Ga-NY104

Targets

CA9 (Carbonic anhydrase IX)

Beyond the preview

Go deeper on 68Ga-NYM005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 68Ga-NYM005.

Explore the full profile